Q3 YTD/FY2024 Financial Results

from the beginning

Q3 YTD/FY2024 Financial Results

Cautionary Statement Regarding Forward-Looking Information

I. Q3 YTD/FY2024 Consolidated Financial Results FY2024 Revised Forecast

• Q3 YTD/FY2024 Financial Results: Key Message

• Q3 YTD/FY2024 Financial Results

• Q3 YTD/FY2024 Financial Results: XTANDI and Strategic Brands

• Business Update: PADCEV, IZERVAY, VYLOY

• Q3 YTD/FY2024 Financial Results: SG&A and R&D Expenses

• FY2024 Revised Forecast

II. Initiatives for Sustainable Growth

• XTANDI and Strategic Brands: FY2024 Key Expected Events

• avacincaptad pegol / IZERVAY: Latest Status

• Progress in Focus Area Approach: Current Status of Programs in Clinical Trial

• Improvement of R&D Productivity

• Progress in Q3 YTD/FY2024 and Latest Outlook

• Upcoming Event

Appendix

• XTANDI and Strategic Brands: Potential Peak Sales (as of Feb 2025)

• Q3 YTD/FY2024 Actual: FX Rate

• FY2024 Forecast: FX Rate & FX Sensitivity

• Balance Sheet & Cash Flow Highlights

• Balance of Bonds and Borrowings Highlights

• Main Intangible Assets (as of Dec 31, 2024)

• Capital Allocation

• Core Basis Performance: Changes in Definitions and Context

• Maximize Potential of Strategic Brands

• Advance Focus Area Approach

• Sustainable Margin Transformation

• Lifecycle Management of Strategic Brands

• Overview of Primary Focus Flagship Programs (1/2)

• Overview of Primary Focus Flagship Programs (2/2)

• Robust Pipeline of Astellas

• Progress in Overall Pipeline

• Strategic Brands: Status Update

• enzalutamide (1/2): Androgen Receptor Inhibitor

• enzalutamide (2/2): Phase 3 Study Data by Disease Stage

• enfortumab vedotin (EV) (1/6): Nectin-4 Targeted ADC Overall UC Program

• enfortumab vedotin (EV) (2/6): Clinical Studies

• enfortumab vedotin (EV) (3/6): Study Data by Disease Stage of UC

• enfortumab vedotin (EV) (4/6): Study Data in 1L mUC (EV-302)

• enfortumab vedotin (EV) (5/6): Study Data in Solid Tumors Other than UC (EV-202)

• enfortumab vedotin (EV) (6/6): Future Outlook

• gilteritinib: FLT3 Inhibitor

• zolbetuximab: Anti-Claudin 18.2 Monoclonal Antibody

• fezolinetant: NK3 receptor antagonist

• avacincaptad pegol (ACP): Complement C5 Inhibitor / Pegylated RNA Aptamer

• On the forefront of healthcare change to turn innovative science into VALUE for patients

Questions

• Questions 1

• Questions 2

• Questions 3

• Questions 4

• Questions 5

• Questions 6

• Questions 7

• Questions 8

• Questions 9